Yuhan Corporation

KOSE:A000100 Stock Report

Market Cap: ₩10.2t

Yuhan Valuation

Is A000100 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000100 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩143.68k
Fair Value
8.1% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: A000100 (₩132100) is trading below our estimate of fair value (₩143678.51)

Significantly Below Fair Value: A000100 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000100?

Key metric: As A000100 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A000100. This is calculated by dividing A000100's market cap by their current revenue.
What is A000100's PS Ratio?
PS Ratio4.7x
Sales₩2.11t
Market Cap₩10.15t

Price to Sales Ratio vs Peers

How does A000100's PS Ratio compare to its peers?

The above table shows the PS ratio for A000100 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13x
A000250 Sam Chun Dang Pharm
18.6xn/a₩4.0t
A128940 Hanmi Pharm
2.5x8.40%₩3.8t
A214370 Caregen
29.4xn/a₩2.5t
A069620 Daewoong Pharmaceutical
1.4x3.53%₩1.9t
A000100 Yuhan
4.7x9.85%₩10.2t

Price-To-Sales vs Peers: A000100 is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (13x).

Price to Sales Ratio vs Industry

How does A000100's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.2xn/aUS$182.19m
A002620 Jeil Pharma Holdings
0.2xn/aUS$100.30m
A000230 Ildong Holdings
0.2xn/aUS$77.27m
A080720 Union Korea Pharm
0.2xn/aUS$10.56m
No more companies available in this PS range
A000100 4.7xIndustry Avg. 0.9xNo. of Companies18PS012345+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A000100 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the KR Pharmaceuticals industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is A000100's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000100 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: A000100 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A000100 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩132,100.00
₩144,375.00
+9.29%
24.98%₩220,000.00₩70,000.00n/a16
Jul ’26₩104,900.00
₩144,625.00
+37.87%
25.05%₩220,000.00₩70,000.00n/a16
Jun ’26₩104,300.00
₩143,588.24
+37.67%
24.65%₩220,000.00₩70,000.00n/a17
May ’26₩113,800.00
₩152,538.46
+34.04%
23.36%₩220,000.00₩70,000.00n/a13
Apr ’26₩110,000.00
₩150,230.77
+36.57%
23.52%₩220,000.00₩70,000.00n/a13
Mar ’26₩121,900.00
₩147,153.85
+20.72%
23.94%₩220,000.00₩80,000.00n/a13
Feb ’26₩129,600.00
₩139,083.33
+7.32%
27.27%₩220,000.00₩75,000.00n/a12
Jan ’26₩119,500.00
₩134,000.00
+12.13%
28.63%₩220,000.00₩75,000.00n/a13
Dec ’25₩115,400.00
₩128,812.50
+11.62%
29.68%₩220,000.00₩75,000.00n/a16
Nov ’25₩134,800.00
₩122,200.00
-9.35%
30.90%₩220,000.00₩75,000.00n/a15
Oct ’25₩142,600.00
₩111,533.33
-21.79%
30.84%₩220,000.00₩67,000.00n/a15
Sep ’25₩141,000.00
₩100,470.59
-28.74%
16.31%₩134,000.00₩67,000.00n/a17
Aug ’25₩92,000.00
₩98,210.53
+6.75%
16.30%₩134,000.00₩67,000.00n/a19
Jul ’25₩83,800.00
₩89,751.88
+7.10%
15.65%₩125,000.00₩65,000.00₩104,900.0019
Jun ’25₩68,800.00
₩87,626.19
+27.36%
15.13%₩125,000.00₩65,000.00₩104,300.0020
May ’25₩72,400.00
₩86,202.49
+19.06%
15.68%₩125,000.00₩65,000.00₩113,800.0020
Apr ’25₩79,200.00
₩83,362.02
+5.26%
11.93%₩110,000.00₩65,000.00₩110,000.0020
Mar ’25₩67,400.00
₩82,612.02
+22.57%
12.44%₩110,000.00₩65,000.00₩121,900.0020
Feb ’25₩59,100.00
₩83,864.78
+41.90%
20.16%₩142,857.14₩66,666.67₩129,600.0019
Jan ’25₩68,800.00
₩82,389.31
+19.75%
21.30%₩142,857.14₩62,585.04₩119,500.0019
Dec ’24₩58,571.43
₩82,606.52
+41.04%
21.73%₩142,857.14₩56,190.48₩115,400.0019
Nov ’24₩55,047.62
₩82,328.04
+49.56%
22.36%₩142,857.14₩56,190.48₩134,800.0018
Oct ’24₩72,190.48
₩82,857.14
+14.78%
15.80%₩119,047.62₩56,190.48₩142,600.0018
Sep ’24₩67,142.86
₩78,897.24
+17.51%
13.26%₩95,238.10₩56,190.48₩141,000.0019
Aug ’24₩71,333.33
₩76,402.12
+7.11%
13.67%₩95,238.10₩56,190.48₩92,000.0018
Jul ’24₩57,523.81
₩69,841.27
+21.41%
10.63%₩85,714.29₩56,190.48₩83,800.0018
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
₩144.38k
Fair Value
8.5% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/18 14:04
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Yuhan Corporation is covered by 35 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Young-Ah HanBofA Global Research
Hyeryeong KimCGS International
Hyonseok KimCLSA